AU2002245474B2 - Monitoring soluble endothelial protein C receptor levels in anticoagulant therapy - Google Patents

Monitoring soluble endothelial protein C receptor levels in anticoagulant therapy Download PDF

Info

Publication number
AU2002245474B2
AU2002245474B2 AU2002245474A AU2002245474A AU2002245474B2 AU 2002245474 B2 AU2002245474 B2 AU 2002245474B2 AU 2002245474 A AU2002245474 A AU 2002245474A AU 2002245474 A AU2002245474 A AU 2002245474A AU 2002245474 B2 AU2002245474 B2 AU 2002245474B2
Authority
AU
Australia
Prior art keywords
sepcr
levels
anticoagulant therapy
protein
thrombin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002245474A
Other languages
English (en)
Other versions
AU2002245474A1 (en
Inventor
Shinichiro Kurosawa
Deborah J. Stearns-Kurosawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU2002245474A1 publication Critical patent/AU2002245474A1/en
Application granted granted Critical
Publication of AU2002245474B2 publication Critical patent/AU2002245474B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002245474A 2001-02-20 2002-02-19 Monitoring soluble endothelial protein C receptor levels in anticoagulant therapy Ceased AU2002245474B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27006601P 2001-02-20 2001-02-20
US60/270,066 2001-02-20
US10/028,741 US7169573B2 (en) 2001-02-20 2001-12-20 Method for monitoring coagulability and hypercoagulable states
US10/028,741 2001-12-20
PCT/US2002/005023 WO2002066981A2 (en) 2001-02-20 2002-02-19 Monitoring soluble endothelial protein c receptor levels in anticoagulant therapy

Publications (2)

Publication Number Publication Date
AU2002245474A1 AU2002245474A1 (en) 2003-02-27
AU2002245474B2 true AU2002245474B2 (en) 2007-05-17

Family

ID=26704034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002245474A Ceased AU2002245474B2 (en) 2001-02-20 2002-02-19 Monitoring soluble endothelial protein C receptor levels in anticoagulant therapy

Country Status (6)

Country Link
US (1) US7169573B2 (enExample)
EP (1) EP1368661A2 (enExample)
JP (1) JP2004530114A (enExample)
AU (1) AU2002245474B2 (enExample)
CA (1) CA2438811A1 (enExample)
WO (1) WO2002066981A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2474630B1 (en) * 2002-12-20 2016-04-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
DK2164514T3 (en) * 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8277804B2 (en) * 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
FR2948666A1 (fr) 2009-07-30 2011-02-04 Univ Paris Curie Methode de diagnostic d'un cancer et de determination de la severite d'un cancer chez un individu
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
EP3673870A3 (en) * 2018-11-09 2020-09-09 Universite Paris Descartes Bioprosthetic tissues and heart valves coated with epcr
CA3153941A1 (en) * 2019-10-17 2021-04-22 Mary POMEROY Coagulation assay apparatus and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804392A (en) * 1997-06-27 1998-09-08 Oklahoma Medical Research Foundation Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
AU8679298A (en) 1998-07-31 2000-02-21 Wallace E. Carroll Method and apparatus for determining anticoagulant therapy factors
US5935802A (en) 1998-08-10 1999-08-10 Evanston Northwestern Healthcare Research Institute Method of assaying a blood sample for prothrombin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804392A (en) * 1997-06-27 1998-09-08 Oklahoma Medical Research Foundation Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood (1998) 91, page 725-727 *

Also Published As

Publication number Publication date
JP2004530114A (ja) 2004-09-30
EP1368661A2 (en) 2003-12-10
WO2002066981A3 (en) 2003-04-24
WO2002066981A2 (en) 2002-08-29
US7169573B2 (en) 2007-01-30
US20060286614A1 (en) 2006-12-21
CA2438811A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
US7169573B2 (en) Method for monitoring coagulability and hypercoagulable states
AU2002245474A1 (en) Monitoring soluble endothelial protein C receptor levels in anticoagulant therapy
Erem et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma
Kuhli-Hattenbach et al. Coagulation disorders and the risk of retinal vein occlusion
Crawley et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels
Souri et al. Anti‐factor XIII A subunit (FXIII‐A) autoantibodies block FXIII‐A2B2 assembly and steal FXIII‐A from native FXIII‐A2B2
US20090298103A1 (en) Predicting hemostatic risk; dependence on plasma composition
Amiral et al. A new assay for global fibrinolysis capacity (GFC): investigating a critical system regulating hemostasis and thrombosis and other extravascular functions
Salvagno et al. Rare thrombophilic conditions
AU690535B2 (en) Novel anticoagulant cofactor activity
Danielsen et al. Activated and total coagulation factor VII, and fibrinogen in coronary artery disease
Laffan et al. 17 Investigation of a thrombotic tendency
CA2757585C (en) Enhanced cleavage of von willebrand factor by adamts13
Hassouna Thrombophilia and hypercoagulability
Lowe et al. Coagulation, fibrinolysis and cardiovascular disease
Hiller Basic principles of hemostasis
Campbell Hemostasis
US20050032140A1 (en) Methods for predicting susceptibility to cardiovascular disease
Dominguez-Reyes et al. Factor XII deficiency in Mexico: high prevalence in the general population and patients with venous thromboembolic disease
US20080274477A1 (en) Forms of Factor Xiia
AU2003295144A1 (en) Detection or determination of variants of factor XIIa
US20030143759A1 (en) Assays for determining anticoagulant cofactor activity
Dumenco et al. The results of diagnostic studies for thrombophilia in a large group of patients with a personal or family history of thrombosis
Ho et al. The serial hemostasis-related changes in patients with cerebral infarction: comparison between progressing and non-progressing stroke
Chighizola et al. Antibodies and diagnostic tests in antiphosholipid syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired